1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Cervical Cancer - Pipeline Review, H1 2016

Cervical Cancer - Pipeline Review, H1 2016

  • May 2016
  • -
  • Global Markets Direct
  • -
  • 441 pages

Cervical Cancer - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Cervical Cancer - Pipeline Review, H1 2016’, provides an overview of the Cervical Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cervical Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cervical Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cervical Cancer
- The report reviews pipeline therapeutics for Cervical Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Cervical Cancer therapeutics and enlists all their major and minor projects
- The report assesses Cervical Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Cervical Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Cervical Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cervical Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Cervical Cancer - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
Introduction 7
Cervical Cancer Overview 8
Therapeutics Development 9
Cervical Cancer - Therapeutics under Development by Companies 11
Cervical Cancer - Therapeutics under Investigation by Universities/Institutes 16
Cervical Cancer - Pipeline Products Glance 17
Cervical Cancer - Products under Development by Companies 20
Cervical Cancer - Products under Investigation by Universities/Institutes 26
Cervical Cancer - Companies Involved in Therapeutics Development 27
Cervical Cancer - Therapeutics Assessment 97
Drug Profiles 112
Cervical Cancer - Recent Pipeline Updates 295
Cervical Cancer - Dormant Projects 415
Cervical Cancer - Discontinued Products 420
Cervical Cancer - Product Development Milestones 421
Appendix 428

List of Tables
Number of Products under Development for Cervical Cancer, H1 2016 21
Number of Products under Development for Cervical Cancer - Comparative Analysis, H1 2016 22
Number of Products under Development by Companies, H1 2016 23
Number of Products under Development by Companies, H1 2016 (Contd..1) 24
Number of Products under Development by Companies, H1 2016 (Contd..2) 25
Number of Products under Development by Companies, H1 2016 (Contd..3) 26
Number of Products under Development by Companies, H1 2016 (Contd..4) 27
Number of Products under Investigation by Universities/Institutes, H1 2016 28
Comparative Analysis by Late Stage Development, H1 2016 29
Comparative Analysis by Clinical Stage Development, H1 2016 30
Comparative Analysis by Early Stage Development, H1 2016 31
Products under Development by Companies, H1 2016 32
Products under Development by Companies, H1 2016 (Contd..1) 33
Products under Development by Companies, H1 2016 (Contd..2) 34
Products under Development by Companies, H1 2016 (Contd..3) 35
Products under Development by Companies, H1 2016 (Contd..4) 36
Products under Development by Companies, H1 2016 (Contd..5) 37
Products under Investigation by Universities/Institutes, H1 2016 38
Cervical Cancer - Pipeline by 3SBio Inc., H1 2016 39
Cervical Cancer - Pipeline by Admedus Ltd, H1 2016 40
Cervical Cancer - Pipeline by Advaxis, Inc., H1 2016 41
Cervical Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2016 42
Cervical Cancer - Pipeline by AnGes MG, Inc., H1 2016 43
Cervical Cancer - Pipeline by Antigen Express, Inc., H1 2016 44
Cervical Cancer - Pipeline by Arbor Vita Corporation, H1 2016 45
Cervical Cancer - Pipeline by ArQule, Inc., H1 2016 46
Cervical Cancer - Pipeline by AstraZeneca Plc, H1 2016 47
Cervical Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H1 2016 48
Cervical Cancer - Pipeline by Azaya Therapeutics, Inc., H1 2016 49
Cervical Cancer - Pipeline by Blirt S.A., H1 2016 50
Cervical Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2016 51
Cervical Cancer - Pipeline by Cancer Research Technology Limited, H1 2016 52
Cervical Cancer - Pipeline by Cellceutix Corporation, H1 2016 53
Cervical Cancer - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016 54
Cervical Cancer - Pipeline by Coherus BioSciences, Inc., H1 2016 55
Cervical Cancer - Pipeline by Critical Outcome Technologies Inc., H1 2016 56
Cervical Cancer - Pipeline by CZ BioMed Corp, H1 2016 57
Cervical Cancer - Pipeline by DelMar Pharmaceuticals, Inc., H1 2016 58
Cervical Cancer - Pipeline by Dr. Reddy's Laboratories Limited, H1 2016 59
Cervical Cancer - Pipeline by EirGenix Inc., H1 2016 60
Cervical Cancer - Pipeline by Eisai Co., Ltd., H1 2016 61
Cervical Cancer - Pipeline by Eureka Therapeutics, Inc., H1 2016 62
Cervical Cancer - Pipeline by EyeGene, Inc., H1 2016 63
Cervical Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 64
Cervical Cancer - Pipeline by Formune S.L., H1 2016 65
Cervical Cancer - Pipeline by Genexine, Inc., H1 2016 66
Cervical Cancer - Pipeline by Genmab A/S, H1 2016 67
Cervical Cancer - Pipeline by Genor BioPharma Co., Ltd., H1 2016 68
Cervical Cancer - Pipeline by Genticel S.A., H1 2016 69
Cervical Cancer - Pipeline by GlaxoSmithKline Plc, H1 2016 70
Cervical Cancer - Pipeline by Immunovaccine, Inc., H1 2016 71
Cervical Cancer - Pipeline by ISA Pharmaceuticals B.V., H1 2016 72
Cervical Cancer - Pipeline by Johnson and Johnson, H1 2016 73
Cervical Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 74
Cervical Cancer - Pipeline by Kite Pharma, Inc., H1 2016 75
Cervical Cancer - Pipeline by LondonPharma Ltd, H1 2016 76
Cervical Cancer - Pipeline by Mabion SA, H1 2016 77
Cervical Cancer - Pipeline by MedImmune, LLC, H1 2016 78
Cervical Cancer - Pipeline by MEI Pharma, Inc., H1 2016 79
Cervical Cancer - Pipeline by Mundipharma International Ltd, H1 2016 80
Cervical Cancer - Pipeline by Mycenax Biotech Inc., H1 2016 81
Cervical Cancer - Pipeline by Nanotherapeutics, Inc., H1 2016 82
Cervical Cancer - Pipeline by Nektar Therapeutics, H1 2016 83
Cervical Cancer - Pipeline by Novartis AG, H1 2016 84
Cervical Cancer - Pipeline by Oncobiologics, Inc., H1 2016 85
Cervical Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 86
Cervical Cancer - Pipeline by Oryx GmbH and Co. KG, H1 2016 87
Cervical Cancer - Pipeline by Otsuka Holdings Co., Ltd., H1 2016 88
Cervical Cancer - Pipeline by PDS Biotechnology Corporation, H1 2016 89
Cervical Cancer - Pipeline by Pfizer Inc., H1 2016 90
Cervical Cancer - Pipeline by Psicofarma S.A. de C.V., H1 2016 91
Cervical Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H1 2016 92
Cervical Cancer - Pipeline by Samyang Holdings Corporation, H1 2016 93
Cervical Cancer - Pipeline by Sanofi, H1 2016 94
Cervical Cancer - Pipeline by Savoy Pharmaceuticals, Inc., H1 2016 95
Cervical Cancer - Pipeline by Seattle Genetics, Inc., H1 2016 96
Cervical Cancer - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H1 2016 97
Cervical Cancer - Pipeline by Shantha Biotechnics Limited, H1 2016 98
Cervical Cancer - Pipeline by Sirnaomics, Inc., H1 2016 99
Cervical Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2016 100
Cervical Cancer - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2016 101
Cervical Cancer - Pipeline by Theravectys SA, H1 2016 102
Cervical Cancer - Pipeline by Tomegavax, Inc., H1 2016 103
Cervical Cancer - Pipeline by UbiVac, LLC, H1 2016 104
Cervical Cancer - Pipeline by Vaccibody AS, H1 2016 105
Cervical Cancer - Pipeline by VLPbio, H1 2016 106
Cervical Cancer - Pipeline by Zeria Pharmaceutical Co., Ltd., H1 2016 107
Cervical Cancer - Pipeline by Zydus Cadila Healthcare Limited, H1 2016 108
Assessment by Monotherapy Products, H1 2016 109
Assessment by Combination Products, H1 2016 110
Number of Products by Stage and Target, H1 2016 112
Number of Products by Stage and Mechanism of Action, H1 2016 117
Number of Products by Stage and Route of Administration, H1 2016 121
Number of Products by Stage and Molecule Type, H1 2016 123
Cervical Cancer Therapeutics - Recent Pipeline Updates, H1 2016 307
Cervical Cancer - Dormant Projects, H1 2016 427
Cervical Cancer - Dormant Projects (Contd..1), H1 2016 428
Cervical Cancer - Dormant Projects (Contd..2), H1 2016 429
Cervical Cancer - Dormant Projects (Contd..3), H1 2016 430
Cervical Cancer - Dormant Projects (Contd..4), H1 2016 431
Cervical Cancer - Discontinued Products, H1 2016 432

List of Figures
Number of Products under Development for Cervical Cancer, H1 2016 21
Number of Products under Development for Cervical Cancer - Comparative Analysis, H1 2016 22
Number of Products under Development by Companies, H1 2016 23
Number of Products under Investigation by Universities/Institutes, H1 2016 28
Comparative Analysis by Late Stage Development, H1 2016 29
Comparative Analysis by Clinical Stage Development, H1 2016 30
Comparative Analysis by Early Stage Products, H1 2016 31
Assessment by Monotherapy Products, H1 2016 109
Assessment by Combination Products, H1 2016 110
Number of Products by Top 10 Targets, H1 2016 111
Number of Products by Stage and Top 10 Targets, H1 2016 111
Number of Products by Top 10 Mechanism of Actions, H1 2016 116
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 116
Number of Products by Top 10 Routes of Administration, H1 2016 120
Number of Products by Stage and Top 10 Routes of Administration, H1 2016 120
Number of Products by Top 10 Molecule Types, H1 2016 122
Number of Products by Stage and Top 10 Molecule Types, H1 2016 122

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Human Papilloma Virus (HPV) E7 Protein - Pipeline Review, H1 2016

Human Papilloma Virus (HPV) E7 Protein - Pipeline Review, H1 2016

  • $ 3 500
  • Company report
  • June 2016
  • by Global Markets Direct

Human Papilloma Virus (HPV) E7 Protein - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Human Papilloma Virus (HPV) E7 Protein - Pipeline Review, H1 2016’, provides in depth analysis ...

Human Papillomavirus Protein E6 (E6) - Pipeline Review, H2 2016

Human Papillomavirus Protein E6 (E6) - Pipeline Review, H2 2016

  • $ 3 500
  • Company report
  • July 2016
  • by Global Markets Direct

Human Papillomavirus Protein E6 (E6) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Human Papillomavirus Protein E6 (E6) - Pipeline Review, H2 2016’, provides in depth analysis on Human ...

XEPTAGEN SpA - Product Pipeline Analysis, 2016 Update

XEPTAGEN SpA - Product Pipeline Analysis, 2016 Update

  • $ 750
  • Company report
  • July 2016
  • by Global Data

Summary Xeptagen SpA (Xeptagen) is a medical device company that discovers molecular markers. The company produces diagnostic kits for the monitoring, detection, and screening of cancerous cells. It develops ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.